Drug Insights

Navigating Health Information: How to Use Synapse to Search for Oxytocin

19 February 2024
2 min read

Oxytocin, an OXTR agonist marketed under the trade name OXYTOCIN®, is a medication that has been lauded for its clinical efficacy in the field of obstetrics and gynecology. Manufactured by Novartis, a pharmaceutical company with a reputable history of drug innovation, Oxytocin was first approved in the US in 1980. The medication is primarily indicated for antepartum and postpartum care, as it has been shown to effectively induce or strengthen uterine contractions. Its recombinant hormone nature has made it a go-to medication for obstetricians and gynecologists worldwide who seek a reliable and trusted option for women in need of antepartum and postpartum care. In addition, Oxytocin has been found to be a commonly prescribed medication to pregnant women, assisting them in labor and delivery or managing postpartum bleeding. Click on the image below to begin the exploration journey of Oxytocin through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

REGENXBIO Hits Key Goal in RGX-121 Study for MPS II
Latest Hotspot
3 min read
REGENXBIO Hits Key Goal in RGX-121 Study for MPS II
19 February 2024
REGENXBIO Confirms Major Milestone Reached in Crucial Study of RGX-121 as Therapy for MPS II, Successfully Hitting Primary Goal.
Read →
Pegfilgrastim: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GI
Pegfilgrastim: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GI
19 February 2024
The initial FOLFIRINOX protocol for PDAC carries a high FN risk; pegfilgrastim mitigates this, but optimal duration is uncertain.
Read →
Initial Human Participant Receives ZMA001 in Medical Study Targeting PAH Therapy
Latest Hotspot
3 min read
Initial Human Participant Receives ZMA001 in Medical Study Targeting PAH Therapy
19 February 2024
Zymedi has begun first human trials of ZMA001, a novel monoclonal antibody for treating Pulmonary Arterial Hypertension.
Read →
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Dopamine
Drug Insights
2 min read
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Dopamine
19 February 2024
Dopamine hydrochloride, first approved in the USA on February 25, 1974, is a medication developed and marketed by Hospira.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.